CDMO– tag –
-
Qihan Biotech Receives FDA RMAT and Breakthrough Therapy Designations for Universal Dual-Target CAR-T Therapy, Supported by PackGene Biotech’s CDMO Expertise
PackGene Biotech China Overview Qihan Biotech announced that its universal dual-target CAR-T therapy received both Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy designations from the U.S. FDA. PackGene Biotech, a... -
Lonza Presents Optimization Strategies to Address Purity and Potency Challenges in In Vivo Lentiviral Vector Development for Cell and Gene Therapies
Biocompare Switzerland Overview Lonza outlined optimization strategies for lentiviral vector (LVV) development for in vivo delivery of cell and gene therapies. Key challenges in LVV development include achieving purity, complexity of val... -
CCRM, OmniaBio, and Avectas Partner to Enhance Cell Therapy Manufacturing with Automated Platform Evaluation
BioSpace Canada Overview CCRM and its CDMO subsidiary, OmniaBio Inc., have partnered with Avectas Limited to evaluate an automated, integrated, and scalable cell therapy manufacturing platform. This collaboration aims to explore how Avec... -
VIVEbiotech Reaches 15 In Vivo Lentiviral Vector Programs, Fortifying Gene Therapy Manufacturing Leadership
BioPharma BoardRoom スペイン Overview VIVEbiotech has significantly advanced its position in gene therapy manufacturing by adding its 15th in vivo lentiviral vector (LVV) therapeutic program. This milestone underscores the company's robu... -
Recipharm Infuses Millions into US Sterile Fill-Finish, Bolstering Advanced Therapy Manufacturing
Recipharm (プレスリリース), Fierce Pharma スウェーデン Overview Global CDMO Recipharm is making a multi-million dollar strategic investment to significantly enhance its US sterile fill-finish capabilities, addressing the surging demand f... -
Hongene Biotech Leverages Chemoenzymatic Ligation to Scale CRISPR sgRNA Manufacturing
Industry Publication / Hongene Biotech Unknown Overview Hongene Biotech is pioneering a chemoenzymatic ligation technology to address the critical scalability challenges in producing single-guide RNA (sgRNA) for CRISPR gene editing. This... -
Cellares Secures $327M in Series D Funding, Including ARK Invest, and Expands Major Manufacturing Agreements with Bristol Myers Squibb and Cabaletta Bio
AllSci USA Overview Cellares has extended its Series D financing to $327 million with a new $50 million investment, specifically aimed at scaling cell therapy manufacturing. As an Integrated Development and Manufacturing Organization (ID... -
CCRM, OmniaBio, and Avectas Collaborate to Automate and Scale Cell Therapy Manufacturing
PR Newswire Canada Overview CCRM and its CDMO subsidiary OmniaBio Inc. have partnered with Avectas Limited to evaluate and integrate Avectas' automated, scalable cell therapy manufacturing platform. This collaboration aims to enhance con... -
Minaris Strengthens Philadelphia GMP Facility, Integrating Cell & Gene Therapy Manufacturing and Testing to Streamline Production
BriefGlance.com USA Overview Minaris, a leading CDMO, has significantly upgraded its GMP cell banking suite at its Philadelphia facility, aiming to streamline cell and gene therapy production. This expansion integrates manufacturing and ... -
VIVEbiotech Scales In Vivo Gene Therapy Portfolio to 15 Programs, Securing Key FDA Clinical Trial Approvals
PharmaSource スペイン Overview Spanish CDMO VIVEbiotech has significantly expanded its in vivo lentiviral vector gene therapy portfolio to 15 programs, several of which have already secured regulatory clearance for clinical trials, inclu...
